title: Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer.
abstract: Imaging has traditionally played a minor role in the diagnosis and staging of prostate cancer. However, recent controversies generated by the use of prostate-specific antigen (PSA) screening followed by random biopsy have encouraged the development of new imaging methods for prostate cancer. Multiparametric magnetic resonance imaging (mpMRI) has emerged as the imaging method best able to detect clinically significant prostate cancers and to guide biopsies. Here, the authors explain what mpMRI is and how it is used clinically, especially with regard to high-risk populations, and we discuss the impact of mpMRI on treatment decisions for men with prostate cancer. CA Cancer J Clin 2016;66:326-336. © 2015 American Cancer Society.
authors.affiliation: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Baris
authors.initials: B
authors.lastname: Turkbey
authors.affiliation: Medical Research Scholars Program, Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Anna M
authors.initials: AM
authors.lastname: Brown
authors.affiliation: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Sandeep
authors.initials: S
authors.lastname: Sankineni
authors.affiliation: National Institutes of Health Center for Interventional Oncology; and Chief, Interventional Radiology Section, National Institutes of Health Clinical Center, Bethesda, MD.
authors.forename: Bradford J
authors.initials: BJ
authors.lastname: Wood
authors.affiliation: Prostate Cancer Section, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Pinto
authors.affiliation: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Choyke
mesh_terms: D019317:Evidence-Based Medicine; D017408:Guidelines as Topic; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D011159:Population Surveillance; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D012680:Sensitivity and Specificity
keywords: active surveillance; high risk; multiparametric magnetic resonance imaging (MRI); prostate cancer